GURU.Markets stock price, segment price, and overall market index valuation
The company's share price iTeos Therapeutics
Intevac produces equipment for hard drive manufacturing. Its stock price reflects its adaptation to the long-term decline of this market and attempts to apply its technologies to new areas, such as protective coatings.
Share prices of companies in the market segment - Pharma immune
iTeos Therapeutics is a biopharmaceutical company developing next-generation immunotherapeutic drugs for cancer treatment. We've categorized it as "Pharma: Immunology." The chart below shows how investors value companies at the forefront of immuno-oncology.
Broad Market Index - GURU.Markets
iTeos Therapeutics is a Belgian oncology company developing next-generation immunotherapy drugs. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how iTeos shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ITOS - Daily change in the company's share price iTeos Therapeutics
For iTeos Therapeutics, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
iTeos Therapeutics is a biopharmaceutical company developing next-generation immuno-oncology drugs. This sector is one of the most advanced and volatile in biotech. The chart below reflects average fluctuations in this industry, serving as a benchmark for valuing iTeos shares.
Daily change in the price of a broad market stock, index - GURU.Markets
iTeos Therapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization iTeos Therapeutics
For iTeos Therapeutics, year-over-year performance is a reflection of its immuno-oncology developments. Its 12-month market cap is entirely dependent on clinical trial data. The partnership with GSK for its anti-TIGIT antibody is key, and its success or failure has a dramatic impact on the company's overall valuation.
Annual dynamics of market capitalization of the market segment - Pharma immune
As an early-stage biotech company, iTeos is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its immunotherapy. Its stock price will reflect investors' speculative faith in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
iTeos Therapeutics, a biopharmaceutical company working in the hot field of immuno-oncology, is a partner of the giant GSK. Its annual market capitalization growth is heavily dependent on the results of joint clinical trials. Success could bring huge payouts and growth unmatched by the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization iTeos Therapeutics
iTeos is an immuno-oncology company. Its monthly performance is driven by progress in clinical trials of its drugs and its partnership with GSK. News of key research milestones are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the biotech sector, specifically immuno-oncology. For iTeos, a clinical-stage company, it serves as a backdrop. Its movements show how investor expectations and news of the partnership with GSK influence its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
iTeos Therapeutics is a biotech company developing next-generation immuno-oncology drugs. Its value depends on the success of clinical trials, often in partnership with major pharmaceutical companies. The overall market chart provides only background information, while iTeos's performance is driven by development news, which is typical for biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization iTeos Therapeutics
iTeos Therapeutics is a Belgian clinical-stage biopharmaceutical company focused on immuno-oncology. Its weekly stock price is volatile, driven by news about clinical trials and its partnership with GSK.
Weekly dynamics of market capitalization of the market segment - Pharma immune
iTeos Therapeutics is another biotech company focused on immuno-oncology. It develops drugs that help the immune system attack cancer cells. The chart helps separate the company's success from industry noise: are the weekly fluctuations driven by iTeos's progress or by general sentiment in the oncology field?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
iTeos is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
ITOS - Market capitalization of the company iTeos Therapeutics
iTeos Therapeutics' market capitalization dynamics reflect investor confidence in its immuno-oncology portfolio. Its volatile chart reflects how investors view its partnership with GSK and the potential of its molecules to become key components in combination cancer therapies.
ITOS - Share of the company's market capitalization iTeos Therapeutics within the market segment - Pharma immune
iTeos Therapeutics is a biotech company working in the hot field of immuno-oncology. Its market share in the pharmaceutical sector is still small, but its developments are attracting considerable attention. Its market capitalization reflects the high potential of its experimental drugs and strategic partnerships with major pharmaceutical companies.
Market capitalization of the market segment - Pharma immune
Here's a chart showing the biotech sector's market capitalization. iTeos Therapeutics is a Belgian company working at the forefront of immuno-oncology. Its research focuses on new targets that can "awaken" the immune system to fight cancer. Its market history exemplifies the global scientific search for new ways to defeat disease.
Market capitalization of all companies included in a broad market index - GURU.Markets
iTeos is a Belgian biopharmaceutical company developing next-generation immuno-oncology drugs. Its market capitalization reflects the potential of its research and development. The chart below shows the economic weight of companies at the forefront of immuno-oncology.
Book value capitalization of the company, segment and market as a whole
ITOS - Book value capitalization of the company iTeos Therapeutics
iTeos's foundation is its intellectual property in a portfolio of immuno-oncology drugs developed in partnership with GSK. The chart tells the story of a biotech company whose balance sheet has been significantly strengthened by upfront payments from a major partner, providing capital for costly clinical trials.
ITOS - Share of the company's book capitalization iTeos Therapeutics within the market segment - Pharma immune
iTeos Therapeutics develops immuno-oncology drugs. The chart shows its share of actual R&D assets. These are its laboratories where they search for new targets that can "awaken" the immune system to fight cancer.
Market segment balance sheet capitalization - Pharma immune
iTeos Therapeutics is a biotech company working in the field of immuno-oncology. Their main assets are patents and clinical trial results, not manufacturing facilities. A book value chart will show the value of their laboratories, but it won't reflect the potential of their research.
Book value of all companies included in the broad market index - GURU.Markets
iTeos Therapeutics' balance sheet includes laboratories and R&D centers for developing next-generation immuno-oncology drugs. The chart shows how the company built its scientific and material foundation for creating innovative cancer treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - iTeos Therapeutics
iTeos Therapeutics is a biotech company working in the hot field of immuno-oncology. Its assets are scientific developments. The chart below visualizes the hopes for a new blockbuster cancer treatment. The dynamics will be determined by news from the lab, not the factory.
Market to book capitalization ratio in a market segment - Pharma immune
iTeos Therapeutics is a clinical-stage biotech company specializing in the development of next-generation immuno-oncology therapeutics. Its valuation is based on the potential of its partnership with a major pharmaceutical company and its own developments. The chart reflects these high investor expectations for its scientific platform.
Market to book capitalization ratio for the market as a whole
iTeos Therapeutics develops immuno-oncology drugs. Like most research-stage biotechs, its market value reflects investors' faith in its science. This chart shows the vast gap between its market capitalization, based on future potential, and its current assets.
Debts of the company, segment and market as a whole
ITOS - Company debts iTeos Therapeutics
iTeos Therapeutics is a Belgian clinical-stage biotech focused on immuno-oncology. This chart demonstrates its strong financial position thanks to its major partnership with GSK. This allows it to fund extensive clinical trials of its drug candidates without the need for frequent capital raising.
Market segment debts - Pharma immune
iTeos Therapeutics is a biotech company working in the hot field of immuno-oncology. The company develops drugs that help the immune system fight cancer. This graph reflects the high expectations and significant financial investments typical of companies at the forefront of cancer science.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio iTeos Therapeutics
iTeos Therapeutics is a clinical-stage immuno-oncology company. This chart shows its financial structure. In this highly competitive field, which requires massive investment, debt is an unaffordable luxury. Equity financing is essential.
Market segment debt to market segment book capitalization - Pharma immune
iTeos Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology drugs. This chart shows the debt burden in the biotech sector. It is a key indicator of the company's ability to fund its expensive research and development in this highly competitive field.
Debt to book value of all companies in the market
iTeos Therapeutics is a clinical-stage biotech company specializing in immuno-oncology. Partnerships with major pharmaceutical companies are essential for its financing. This graph of total market debt serves as an indicator of the overall risk appetite in the economy, which may influence the willingness of major companies to invest in risky projects.
P/E of the company, segment and market as a whole
P/E - iTeos Therapeutics
iTeos Therapeutics is a biotechnology company developing a new generation of immuno-oncology drugs. This chart reflects the high risks and potential associated with innovative approaches to cancer treatment. The company's performance is entirely dependent on clinical trial results and partnerships with major pharmaceutical companies.
P/E of the market segment - Pharma immune
iTeos Therapeutics is a clinical-stage biotech company developing a new generation of immuno-oncology drugs. Its goal is to create drugs that will be effective for patients who do not respond to existing therapies. This chart shows the average valuation for the pharmaceutical sector, reflecting investor expectations for the next generation of cancer treatments.
P/E of the market as a whole
iTeos Therapeutics is a biotech company developing next-generation immuno-oncology drugs. Its valuation is a pure bet on the success of its scientific platform. It has no connection to the general economic cycles depicted by this chart. iTeos's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company iTeos Therapeutics
iTeos Therapeutics is a biopharmaceutical company developing next-generation immuno-oncology drugs aimed at enhancing the immune system's effectiveness in fighting cancer. This chart reflects investors' faith in its scientific approach. Future profits depend on the success of clinical trials.
%20P%2FE%20iTeos%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-iTeos-Therapeutics&v=1772598036036 "Chart of the company's future (projected) P/E iTeos Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
iTeos Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of immuno-oncology therapeutics. The chart reflects average expectations for the oncology segment. iTeos's position relative to this benchmark reflects investor assessment of their scientific approach, which targets new pathways in the immune system to fight cancer.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772598036076 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
iTeos Therapeutics is a Belgian clinical-stage biopharmaceutical company developing a new generation of immuno-oncology drugs. The company is focused on new mechanisms to make immunotherapy effective for more patients. This chart of overall market expectations shows how willing investors are to fund cutting-edge scientific approaches in oncology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772598036118 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit iTeos Therapeutics
iTeos Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of immuno-oncology therapeutics. Its financial structure is comprised of research expenses and revenue from a major partnership with GSK. Potential profitability depends on the success of its innovative candidates.
Profit of companies in the market segment - Pharma immune
iTeos Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of immuno-oncology drugs aimed at overcoming resistance to existing therapies. This chart shows the overall profitability of the immunopharmaceutical industry, indicating the industry's success in developing innovative combinations and approaches for cancer treatment.
Overall market profit
iTeos Therapeutics is a biotech company developing a new generation of immuno-oncology drugs. Its goal is to overcome resistance to existing treatments. The company's success depends on the results of clinical trials. The positive economic backdrop, visible in this chart, is critical for attracting investment in this highly competitive field.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company iTeos Therapeutics
iTeos Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of immuno-oncology drugs. This chart reflects analysts' speculative expectations regarding the potential of its scientific approaches aimed at enhancing the immune system's effectiveness in fighting cancer.
%20profit%20of%20the%20company%20iTeos%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-iTeos-Therapeutics&v=1772598036205 "Graph of future (projected) profit of the company iTeos Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
iTeos Therapeutics is a biotech company developing a new generation of immuno-oncology drugs aimed at overcoming resistance to existing treatments. The company's future depends on the success of clinical trials. This chart reflects forecasts for the entire biotech sector, providing context for assessing the potential and risks of iTeos's innovative approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772598036215 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
iTeos Therapeutics is a biotechnology company developing immuno-oncology drugs. Its value and future are determined solely by the results of clinical trials and the potential of its scientific developments. The general macroeconomic indicators presented in this chart are irrelevant.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772598036258 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - iTeos Therapeutics
iTeos Therapeutics is a clinical-stage biotech focused on immuno-oncology. Its high valuation, as seen on this chart, reflects the strong interest in its developments, especially in the context of its partnership with a major pharmaceutical company. Its performance is dependent on the results of joint clinical trials.
P/S market segment - Pharma immune
iTeos Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of immuno-oncology therapeutics. Future revenue depends on the success of its innovative developments. This pharma-specific chart reflects investor expectations for iTeos's potential to develop breakthrough treatments that could enhance the response to immunotherapy.
P/S of the market as a whole
iTeos Therapeutics is a clinical-stage biotech company developing a new generation of immuno-oncology therapeutics. Its research is aimed at overcoming tumor resistance to existing immunotherapies. This market revenue valuation chart helps understand how investors value this cutting-edge scientific approach.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company iTeos Therapeutics
iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation immuno-oncology therapeutics. This chart shows how the market perceives the future commercial potential of its innovative cancer treatment approaches. It reflects expectations for the success of clinical trials and partnerships.
%20P%2FS%20iTeos%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-iTeos-Therapeutics&v=1772598036325 "The graph of the company's future (projected) P/S iTeos Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
iTeos Therapeutics is a clinical-stage biotechnology company focused on developing next-generation immuno-oncology therapeutics. The company's valuation, particularly in the context of its partnership with GSK, reflects high expectations for its lead candidates, which could be a significant addition to existing cancer treatments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772598036328 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
iTeos Therapeutics is a biotech company developing a new generation of immuno-oncology drugs. Its goal is to overcome resistance to existing therapies. Given the overall revenue projections shown in the chart, iTeos represents a venture capital investment in the future of cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772598036331 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales iTeos Therapeutics
iTeos Therapeutics is a clinical-stage immuno-oncology company. It has no commercial products, and its revenue, reflected in this chart, is generated through large upfront payments and milestone payments as part of a strategic partnership with GlaxoSmithKline to develop a new drug.
Sales of companies in the market segment - Pharma immune
iTeos Therapeutics (ITOS) is a biopharmaceutical company developing a new generation of immuno-oncology drugs. Its goal is to create therapies that overcome resistance to existing checkpoint inhibitors. This metric reflects revenue in the immunology pharmaceutical sector. iTeos operates at the forefront of cancer treatment science.
Overall market sales
iTeos Therapeutics is a biotech company developing a new generation of immuno-oncology drugs. Its market capitalization depends on progress in clinical trials. This overall economic activity profile influences investors' risk appetite. During periods of growth, they are more willing to invest in the innovative cancer treatment approaches iTeos offers.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company iTeos Therapeutics
iTeos Therapeutics is a biotechnology company developing a new generation of immuno-oncology drugs aimed at improving the effectiveness of cancer treatment. Its future revenue depends on the success of clinical trials and partnerships. This chart reflects analyst forecasts, which essentially assess the commercial potential of its innovative scientific approaches in oncology.
%20sales%20of%20the%20company%20iTeos%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-iTeos-Therapeutics&v=1772598036415 "Schedule of future (projected) sales of the company iTeos Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation immuno-oncology therapeutics. This forecast chart reflects the potential future revenue from their pipeline of candidates. It represents analysts' views on the commercial prospects of their research and development efforts.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772598036443 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
iTeos Therapeutics is a Belgian biotech company developing a new generation of immuno-oncology drugs. Its goal is to make immunotherapy effective for more patients. This chart reflects the overall investment climate, and iTeos's research progress is a bet on a scientific breakthrough that could expand the application of one of the key advances in cancer treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772598036453 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality iTeos Therapeutics
iTeos Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of immuno-oncology drugs. Its financial performance reflects significant investment in research. The chart shows current profitability as an investment in the development of innovative cancer treatments that could generate significant future profits.
Market segment marginality - Pharma immune
iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation immuno-oncology therapeutics. This chart reflects its operating expenses. Success depends on clinical trial results and potential partnerships with major pharmaceutical companies to bring the drugs to market.
Market marginality as a whole
iTeos Therapeutics is a clinical-stage biotechnology company developing a new generation of immuno-oncology therapies. This total return chart reflects the investment climate. During periods of economic growth and market optimism, investors are more willing to fund breakthrough, but high-risk, cancer treatment projects.
Employees in the company, segment and market as a whole
Number of employees in the company iTeos Therapeutics
iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new generation of immuno-oncology drugs. Its goal is to overcome resistance to existing treatments. This graph shows a team of scientists working on developing innovative combinations to fight cancer.
Share of the company's employees iTeos Therapeutics within the market segment - Pharma immune
iTeos Therapeutics is a clinical-stage biotechnology company developing a new generation of immuno-oncology drugs. Its core asset is its team of scientists. This chart shows the company's investment in complex scientific research, aiming to overcome the limitations of existing cancer immunotherapies.
Number of employees in the market segment - Pharma immune
iTeos Therapeutics is developing next-generation immuno-oncology drugs. This chart, showing activity in the immunopharmacology sector, illustrates the intense race to create more effective cancer treatments. For iTeos, with its innovative molecules, growth in this field represents both enormous scientific potential and intense competition.
Number of employees in the market as a whole
iTeos Therapeutics is a biotechnology company developing a new generation of immuno-oncology drugs. Funding such cutting-edge research requires a favorable investment climate. The growth in overall employment, reflected in this chart, is a sign of a healthy economy where investors are willing to support long-term, capital-intensive research projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company iTeos Therapeutics (ITOS)
iTeos Therapeutics (ITOS) is a biotech company working in the field of immuno-oncology. This chart shows the valuation of their unique R&D platform. Market capitalization is not tied to headcount but rather reflects the success of their technology. This is pure intellectual capital, which translates into a high valuation per employee.
%20of%20the%20company%20iTeos%20Therapeutics%20(ITOS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-iTeos-Therapeutics-ITOS&v=1772598036573 "Chart of market capitalization per employee (in thousands of dollars) of the company iTeos Therapeutics (ITOS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
iTeos Therapeutics is a biotech company specializing in immuno-oncology. Its market capitalization is based on the potential of its clinical pipeline. This metric demonstrates the future value the market places on the work of each scientist who can create a new generation of cancer drugs.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772598036595 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
iTeos Therapeutics is a clinical-stage biotech company focused on developing next-generation immuno-oncology therapeutics. Its valuation depends on the success of its research. This chart for iTeos is a prime example of a biotech company where the market value per employee can be colossal, reflecting the company's hopes for breakthrough cancer treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772598036616 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company iTeos Therapeutics (ITOS)
iTeos Therapeutics is a biotech R&D company working in the field of immuno-oncology. The company is unprofitable. This graph will show a negative value—the loss per scientist. This reflects the high cost of cutting-edge research in this field.
%20Chart%20iTeos%20Therapeutics%20(ITOS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-iTeos-Therapeutics-ITOS&v=1772598036635 "Company Profit Per Employee (in thousands of dollars) Chart iTeos Therapeutics (ITOS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
iTeos Therapeutics is a biotech company focused on immuno-oncology. The productivity of the scientific team is crucial in this highly competitive field. This graph shows the potential value each employee creates, which is an indicator of the company's investment in developing next-generation cancer drugs.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772598036678 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
iTeos Therapeutics is a biotech company developing next-generation immuno-oncology drugs designed to improve the effectiveness of existing cancer treatments. This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772598036704 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee iTeos Therapeutics (ITOS)
iTeos Therapeutics is a clinical-stage biotech developing immuno-oncology drugs. Its revenue comes from major partnerships with pharma giants like GSK. The chart shows these upfront and milestone payments, which fund its expensive clinical trials before market entry.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-iTeos-Therapeutics-ITOS&v=1772598036731 "Sales chart per company employee iTeos Therapeutics (ITOS)")
Sales per employee in the market segment - Pharma immune
iTeos Therapeutics (ITOS) is a biotech company specializing in the development of next-generation immuno-oncology drugs (e.g., TIGIT inhibitors). This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and capital utilization compared to other immuno-oncology companies.
Sales per employee for the market as a whole
iTeos Therapeutics (ITOS) is a clinical-stage biotechnology company focused on developing next-generation immuno-oncology therapeutics. The company has no commercial revenue but has major partnerships (for example, with GSK). This metric reflects revenue from these partnerships (milestone payments) per R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company iTeos Therapeutics (ITOS)
iTeos Therapeutics (ITOS) is a clinical-stage biotech company working in the hot but crowded field of immuno-oncology (e.g., TIGIT inhibitors). This chart shows short interest. The high bearish bets reflect concerns that their candidates will not stand out against drugs from giants (Roche, GSK) and a high risk of clinical failure. (349)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-iTeos-Therapeutics-ITOS&v=1772598036813 "Short Shares Chart for the Company iTeos Therapeutics (ITOS)")
Shares shorted by market segment - Pharma immune
iTeos Therapeutics (ITOS) is a biopharmaceutical company developing next-generation immuno-oncology drugs. The chart below represents a general short position in the oncology biotech sector. It demonstrates the general investor skepticism regarding the success of risky clinical trials in this field.
Shares shorted by the overall market
iTeos Therapeutics is a clinical-stage biotech focused on immuno-oncology. When this chart shows rising fears, speculative, pre-profitable companies are the first to suffer. Investors are unwilling to wait years for FDA approval. They see iTeos as a money-burner and are selling off shares, fearing the company will be unable to attract new capital in a risk-off environment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator iTeos Therapeutics (ITOS)
iTeos Therapeutics is a biotech company working in the hot field of immuno-oncology. This chart shows the pulse of their R&D. Investor interest spiked on data about their TIGIT candidate and partnership with GSK, then cooled amid mixed industry data.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-iTeos-Therapeutics-ITOS&v=1772598036886 "RSI 14 indicator chart for the company's stock iTeos Therapeutics (ITOS)")
RSI 14 Market Segment - Pharma immune
iTeos Therapeutics is a Belgian biopharmaceutical company specializing in immuno-oncology. It is developing a new generation of drugs (including antibodies) that activate the immune system against cancer. This chart measures the overall momentum of the immunology biotech sector. It clearly shows when this entire niche is overhyped or oversold.
RSI 14 for the overall market
iTeos Therapeutics (ITOS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ITOS (iTeos Therapeutics)
iTeos Therapeutics is a Belgian biotech focused on developing next-generation immuno-oncology therapeutics (targeting TIGIT and A2Ar). This chart shows the speculative average 12-month price target from analysts, which is almost entirely based on their assessment of the company's R&D portfolio and partnerships (GSK).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ITOS-iTeos-Therapeutics&v=1772598036976 "A chart showing analyst consensus forecasts for the expected stock price. ITOS (iTeos Therapeutics)")
The difference between the consensus estimate and the actual stock price ITOS (iTeos Therapeutics)
iTeos (ITOS) is a biotech company (in partnership with GSK) at the forefront of immuno-oncology, developing a new generation of drugs (TIGIT). This chart shows how far the current share price differs from its "fair" value. It reflects analysts' binary belief in the success of this R&D race and their mega-partnership.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ITOS-iTeos-Therapeutics&v=1772598037017 "A chart showing the difference between the consensus forecast and the actual stock price. ITOS (iTeos Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
iTeos (ITOS) is a biotech company seeking to develop the "next generation" of immuno-oncology drugs, famous for developing the TIGIT inhibitor in collaboration with GSK. This chart reflects the collective opinion of the entire immunopharmaceutical R&D sector. It shows whether experts believe a "new Keytruda" has been found or whether they consider the field saturated.
Analysts' consensus forecast for the overall market share price
iTeos Therapeutics is a biotech company specializing in the development of next-generation cancer immunotherapy. This is a high-risk sector. This chart reflects the overall market "risk appetite." For iTeos, a clinical-stage company, overall market optimism (the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index iTeos Therapeutics
iTeos is a biotech R&D company focused on immuno-oncology. Their specialty is the R&D of drugs (antibodies) targeting new checkpoints (TIGIT, A2A), which (in combination with Keytruda) are expected to stimulate immunity against cancer. (Their key partner is GSK.) This chart is a pure R&D barometer of faith/fear. It reflects the market's assessment of their (very risky) clinical data.
AKIMA Market Segment Index - Pharma immune
iTeos Therapeutics is an immuno-oncology company. They are developing drugs (TIGIT inhibitors) that are designed to awaken the immune system and force it to attack cancer. This is a hot area in pharma-immuno. This chart compares their composite index to the sector, showing how their approach compares to others.
The AKIM Index for the overall market
iTeos Therapeutics is an immuno-oncology company developing therapies targeting the adenosine pathway (TIGIT, A2A). A GSK partner, this chart, which reflects the market average, provides a macro backdrop. It helps assess how this well-funded research company stacks up against broader economic trends.
